Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Regulatory Filings Classification · 87% confidence The document is a U.S. SEC Form 8-K “Current Report” under the Exchange Act, primarily furnishing an earnings press release as Exhibit 99.1. It is a standard regulatory compliance filing rather than the earnings release itself or a detailed financial report. There is no substantive financial data or corporate presentation content in-line. This does not fit the specific earnings release category (ER) because the press release content is only referenced, nor does it match any board, financing, or governance category. Therefore it is best classified as a general regulatory filing (RNS).
2026-05-14 English
ARS - Pyxis Oncology, Inc. (0001782223) (Filer)
Annual Report
2026-04-30 English
DEF 14A - Pyxis Oncology, Inc. (0001782223) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
8-K/A - Pyxis Oncology, Inc. (0001782223) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC, which is a Current Report. The content focuses on the departure of a CEO and director, including details about a Separation Agreement and related compensatory arrangements. There are no financial statements or detailed financial performance data presented. The primary subject is a management change and related agreements. According to the filing definitions, announcements of changes in senior management or board members fall under Board/Management Information (MANG). The document length is under 5,000 characters and it is not an announcement of a report publication but a substantive update on management changes. Therefore, the correct classification is MANG with high confidence.
2026-04-30 English
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
Director's Dealing
2026-03-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.